Delving into the Latest Updates on Choriogonadotropin beta with Synapse

Overview

Basic Info

Drug Type

Hormone

Synonyms

Novarel, Recombinant human chorionic gonadotropin

+ [1]

Target

FSHR x LHCGR

Mechanism

FSHR agonists(Follicle-stimulating hormone receptor agonists), LHCGR agonists(Luteinizing hormone/Choriogonadotropin receptor agonists)

Therapeutic Areas

Urogenital Diseases

Active Indication

Infertility

Inactive Indication-

Originator Organization

Ferring BV

Active Organization

Ferring Pharmaceuticals SA

Inactive Organization

Ferring Pharmaceuticals A/S

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 51997β

Source: *****

Sequence Code 3246α

Source: *****

A Randomised, Double-blind, Placebo-controlled, Parallel-group Exploratory Trial to Investigate the Effect of FE 999302 When Administered During Different Time Intervals in Women Undergoing Controlled Ovarian Stimulation With a Fixed Dose of Follitropin Delta in a Gonadotropin-releasing Hormone Antagonist Protocol.

This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle). The trial is a randomised, double blind, placebo controlled, parallel group, exploratory trial, investigating the effect of FE 999302 when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a antagonist protocol.

Start Date15 Jul 2024

Sponsor / Collaborator

Ferring Pharmaceuticals SA

CTIS2023-507630-25-00 / Recruiting

- 000426

Start Date21 Jun 2024

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

100 Clinical Results associated with Choriogonadotropin beta

Login to view more data

100 Translational Medicine associated with Choriogonadotropin beta

Login to view more data

100 Patents (Medical) associated with Choriogonadotropin beta

Login to view more data

119

Literatures (Medical) associated with Choriogonadotropin beta

20 Sep 2023·Cureus

In Vitro Fertilization Outcomes With a Dual Trigger in Normoresponders in Antagonist Cycles

Article

Author: Erdem, Ahmet ; Demirdağ, Erhan ; Erdem, Mehmet ; Cevher Akdulum, Munire Funda ; Arık, Seçil İrem

Objectives To evaluate whether the dual trigger of ovulation with a gonadotropin-releasing hormone (GnRH) agonist and the standard dose of recombinant human chorionic gonadotropin (hCG) (dual trigger) is better than hCG alone in in vitro fertilization (IVF) cycles of patients who responded well to ovarian stimulation. Methods Between January 2013 and December 2021, 5593 antagonist cycles of patients were reviewed. This study included women who had an antral follicle count of 5 or more and exhibited a normoresponse to ovarian stimulation using the GnRH antagonist protocol, as determined by the follicular output rate (FORT). The primary outcome indicators consisted of the quantities of retrieved oocytes and mature oocytes. The secondary outcome markers included live birth rates, clinical pregnancy rates, and continued pregnancy rates. Results A total of 1244 normoresponder women who met the inclusion criteria were identified from the scanned files and subsequently enrolled in the GnRH antagonist protocol. A total of 383 cycles were observed in the group that was given the standard hCG trigger while 861 cycles were observed in the group that was given the dual trigger. The number of mature oocytes and top-quality embryos was significantly higher in the dual trigger group. The maturation rate in the hCG group was 74.8% while it was 76.9% in the dual trigger group (p=0.018). The dual trigger group exhibited an ongoing pregnancy rate of 37.6%, whereas the hCG group had a rate of 30.1% (p = 0.02). The dual trigger group exhibited a slightly higher live birth rate (34.3% vs 29.2%, p = 0.11), although this difference did not reach statistical significance. Conclusion Dual trigger of ovulation was superior to hCG alone in terms of the number of mature oocytes yielded, top quality of embryos, maturation rates, and ongoing pregnancy in IVF cycles of normoresponders having ovarian stimulation on the GnRH antagonist protocol.

01 May 2023·International journal of reproductive biomedicine

Does dual trigger improve euploidy rate in normoresponder? A cross-sectional study.

Article

Author: Ece Utkan Korun, Zeynep ; Yazicioglu, Caglar ; Yuceturk, Aysen ; Karaosmanoglu, Ozge ; Cakiroglu, Yigit ; Tiras, Bulent ; Yildirim Kopuk, Sule

BackgroundWith the introduction of the dual triggering-gonadotropin-releasing hormone (GnRH) analog and recombinant human chorionic gonadotropin (hCG) combination, women with a history of low mature oocyte proportion and empty follicle syndrome were shown to benefit from the dual trigger.ObjectiveTo investigate whether dual triggering of oocyte maturation with a GnRH agonist (GnRHa) combined with hCG can affect the euploidy rate and improve in vitro fertilization outcomes for normoresponder women.Materials and MethodsIn this cross-sectional study, 494 women who underwent controlled ovarian stimulation with hCG (n = 274) or dual triggering (hCG+GnRHa, n = 220) at Acibadem Maslak hospital, Assisted Reproductive Unit, from January 2019-2022 were enrolled in this study. Preimplantation genetic testing for aneuploidy was performed on all participants.ResultsBoth groups had similar baseline and clinical characteristics. Of the 881 embryos biopsied, 312 (35.4%) were reported as euploid in the hCG trigger group; in the dual trigger group, 186 (29.8%) of 623 screening embryos were reported as euploid. The hCG group had a higher euploidy rate per biopsied embryo, although the difference was not statistically significant (31.4 __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__± 26.5 vs. 26.5 __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__± 33.3, p __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__> 0.05).ConclusionIn normoresponders, adding GnRHa for final follicular maturation to hCG did not improve the euploidy rate.

01 Mar 2023·Journal of Assisted Reproduction and Genetics

Recombinant human chorionic gonadotropin and gonadotropin-releasing hormone agonist differently affect the profile of extracellular vesicle microRNAs in human follicular fluid

Article

Author: Machtinger, R ; Hauser, R ; Racowsky, C ; Barnett-Itzhaki, Z ; Baccarelli, A A ; Bollati, V ; Orvieto, R

PURPOSETo compare the expression profile of extracellular vesicle microRNAs (EV-miRNAs) derived from follicular fluid after a trigger with recombinant human chorionic gonadotropin (r-hCG) or with a gonadotropin-releasing hormone GnRH agonist (GnRH-a) for final oocyte maturation.METHODSA retrospective analysis of a prospective cohort. Women undergoing in vitro fertilization at a tertiary university-affiliated hospital were recruited between 2014 and 2016. EV-miRNAs were extracted from the follicular fluid of a single follicle, and their expression was assessed using TaqMan Open Array®. Genes regulated by EV-miRNAs were analyzed using miRWalk2.0 Targetscan database, DAVID Bioinformatics Resources, Kyoto-Encyclopedia of Genes and Genomes (KEGG), and Gene Ontology (GO).RESULTSEighty-two women were included in the r-hCG trigger group and 9 in the GnRH-a group. Of 754 EV-miRNAs screened, 135 were detected in at least 50% of the samples and expressed in both groups and were further analyzed. After adjusting for multiple testing, 41 EV-miRNAs whose expression levels significantly differed between the two trigger groups were identified. Bioinformatics analysis of the genes regulated by these EV-miRNAs showed distinct pathways between the two triggers, including TGF-beta signaling, cell cycle, and Wnt signaling pathways. Most of these pathways regulate cascades associated with apoptosis, embryo development, implantation, decidualization, and placental development.CONCLUSIONSTrigger with GnRH-a or r-hCG leads to distinct EV-miRNAs expression profiles and to downstream biological effects in ovarian follicles. These findings may provide an insight for the increased apoptosis and the lower implantation rates following GnRH-a trigger vs. r-hCG in cases lacking intensive luteal phase support.

100 Deals associated with Choriogonadotropin beta

Login to view more data